Find Isavuconazonium Sulfate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

0

South Africa

0

Listed Dossiers

FDF DossiersDRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 946075-13-4, Cresemba, Isavuconazonium (sulfate), Bal-8557-002, Isavuconazonium sulfate [usan], Chebi:85977
Molecular Formula
C35H36F2N8O9S2
Molecular Weight
814.8  g/mol
InChI Key
LWXUIUUOMSMZKJ-KLFWAVJMSA-M
FDA UNII
31Q44514JV

Isavuconazonium Sulfate
Isavuconazonium Sulfate is the sulfate ester form of isavuconazonium, a prodrug of the triazole antifungal agent isavuconazole, with broad-spectrum antifungal activity. Upon administration, isavuconazonium sulfate is hydrolyzed by plasma esterases to yield the active moiety isavuconazole. Isavuconazole binds to and inhibits the fungal cytochrome P450 family enzyme lanosterol 14-alpha-demethylase (CYP51), which catalyzes the demethylation of lanosterol to yield ergosterol, an important component of the fungal cell membrane. Inhibition of CYP51 leads to a decrease in fungal ergosterol production and disrupts synthesis of the fungal cell membrane, which decreases membrane integrity, increases cell membrane permeability and promotes the loss of essential intracellular elements. This results in fungal cell lysis and death.
1 2D Structure

Isavuconazonium Sulfate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]pyridin-3-yl]methyl 2-(methylamino)acetate;hydrogen sulfate
2.1.2 InChI
InChI=1S/C35H35F2N8O5S.H2O4S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3;1-5(2,3)4/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3;(H2,1,2,3,4)/q+1;/p-1/t22-,23?,35+;/m0./s1
2.1.3 InChI Key
LWXUIUUOMSMZKJ-KLFWAVJMSA-M
2.1.4 Canonical SMILES
CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O.OS(=O)(=O)[O-]
2.1.5 Isomeric SMILES
C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O.OS(=O)(=O)[O-]
2.2 Other Identifiers
2.2.1 UNII
31Q44514JV
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-((2r,3r)-3-(4-(4-cyanophenyl)-1,3-thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-((1rs)-1-((methyl(3-((((methylamino)acetyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1h-1,2,4-triazol-4-ium Monosulfate

2. 4-(2-((2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)-1,3-thiazol-4-yl)benzonitrile

3. Ak-1820

4. Ak1820

5. Bal 4815

6. Bal 8557

7. Bal-4815

8. Bal-8557

9. Bal-8557-002

10. Bal4815

11. Bal8557

12. Bal8557-002

13. Cresemba

14. Isavuconazole

2.3.2 Depositor-Supplied Synonyms

1. 946075-13-4

2. Cresemba

3. Isavuconazonium (sulfate)

4. Bal-8557-002

5. Isavuconazonium Sulfate [usan]

6. Chebi:85977

7. Ak1820

8. 31q44514jv

9. Ak-1820

10. Bal8557-002

11. [2-[1-[1-[(2r,3r)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]pyridin-3-yl]methyl 2-(methylamino)acetate;hydrogen Sulfate

12. 1-((2r,3r)-3-(4-(4-cyanophenyl)-1,3-thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-((1rs)-1-((methyl(3-((((methylamino)acetyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1h-1,2,4-triazol-4-ium Monosulfate

13. Glycine, N-methyl-, (2-(((1-(1-((2r,3r)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4h-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl Ester, Sulfate (1:1)

14. Isavuconazonium Sulfate (usan)

15. 1-((2r,3r)-3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-(1-((methyl(3-(((methylglycyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1h-1,2,4-triazol-4-ium Hydrogen Sulfate

16. Unii-31q44514jv

17. Chembl3137333

18. Dtxsid901026216

19. Ex-a1786

20. Isavuconazonium Sulfate [jan]

21. Akos030527357

22. Isavuconazonium Sulfate [who-dd]

23. Ac-31126

24. As-35043

25. Hy-100373

26. Cs-0018702

27. Isavuconazonium Sulfate [orange Book]

28. D10643

29. A900138

30. Q27158829

31. (2-{[(1-{1-[(2r,3r)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1h-1,2,4-triazol-4-ium-4-yl}ethoxy)carbonyl](methyl)amino}pyridin-3-yl)methyl N-methylglycinate Hydrogen Sulfate

2.4 Create Date
2013-12-16
3 Chemical and Physical Properties
Molecular Weight 814.8 g/mol
Molecular Formula C35H36F2N8O9S2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count17
Rotatable Bond Count15
Exact Mass814.20147343 g/mol
Monoisotopic Mass814.20147343 g/mol
Topological Polar Surface Area273 Ų
Heavy Atom Count56
Formal Charge0
Complexity1290
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

Treatment of invasive aspergillosis, Treatment of mucormycosis


Treatment of Candida infections


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antifungal Agents

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Azoles [CS]; Cytochrome P450 3A4 Inhibitors [MoA]; Organic Cation Transporter 2 Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Azole Antifungal [EPC]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Flag Poland
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 38964

Submission : 2023-10-04

Status : Active

Type : II

Polpharma CB

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2023-11-08

Pay. Date : 2023-09-28

DMF Number : 38781

Submission : 2023-09-22

Status : Active

Type : II

Biophore

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39823

Submission : 2024-04-30

Status : Active

Type : II

Metrochem

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36974

Submission : 2022-05-06

Status : Active

Type : II

Metrochem

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2024-02-12

Pay. Date : 2024-01-05

DMF Number : 38784

Submission : 2023-09-30

Status : Active

Type : II

Company Banner

06

Arvo
Not Confirmed

06

Arvo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-06-28

Pay. Date : 2024-06-13

DMF Number : 38251

Submission : 2023-03-31

Status : Active

Type : II

blank

07

Arvo
Not Confirmed

07

Arvo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-04-25

Pay. Date : 2024-03-07

DMF Number : 38502

Submission : 2023-10-19

Status : Active

Type : II

blank

08

Cipla Ltd

India

USDMF

arrow
Arvo
Not Confirmed

08

Cipla Ltd

India
arrow
Arvo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-01-26

Pay. Date : 2023-12-13

DMF Number : 39151

Submission : 2023-12-18

Status : Active

Type : II

blank

09

Arvo
Not Confirmed

09

Arvo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2025-01-16

Pay. Date : 2024-12-31

DMF Number : 39496

Submission : 2024-03-28

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...

Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and acts as a sourcing and regulatory marketing agent for API manufacturers. Transo-Pharm assists with DMF setup, GMP consulting, and regulatory activities, supported by a regulatory team, warehouse facilities, proprietary API process IPs, and laboratory partnerships, with offices in Shanghai, Hong Kong, Singapore, and the US. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Transo Pharm USA Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Virupaksha, you get a quality product with on-time delivery.

Flag India
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : Virupaksha Organics, founded in 2003, is a leading manufacturer of APIs and intermediates. Its FDA-audited, ISO-certified facilities in Kazipally and Pashamylaram produce high-qual...

Virupaksha Organics, founded in 2003, is a leading manufacturer of APIs and intermediates. Its FDA-audited, ISO-certified facilities in Kazipally and Pashamylaram produce high-quality products. With 300+ customers in 100 countries, Virupaksha has built a strong global presence and a trusted reputation for reliability. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Virupaksha

03

Polpharma

Poland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Flag Poland
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : Polpharma API, a division of a leading Polish pharmaceutical group, has over 75 years of expertise in process development and cGMP manufacturing. Based at an FDA-approved site in C...

Polpharma API, a division of a leading Polish pharmaceutical group, has over 75 years of expertise in process development and cGMP manufacturing. Based at an FDA-approved site in Central Europe, it offers comprehensive API services from development to scale-up. Specializing in small molecule clinical candidates, Polpharma delivers customized, high-quality solutions with strong regulatory knowledge and advanced infrastructure. Globally recognized for complex chemistry, it is committed to precision, partnership, and progress. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Polpharma CB

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships fo...

ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships for product development, compliance, and secure logistics. ChemWerth accesses over 500 APIs and 30 manufacturing facilities across the US, Europe, India, and China, acts as a regulatory agent for 25+ FDA-approved facilities, sells 100+ products, and operates in 38 countries. In 2020, it filed its 500th DMF with the FDA . Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Chemwerth Compnay Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...

Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&D center of 400 scientists, the company is a leading global API player. Biophore ranks among the top US DMF filers, holds 150+ patents and maintains a strong compliance record with major regulatory agencies. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Biophore

06

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTranso-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Flag Germany
Digital Content Digital Content

Isavuconazonium Sulphate

About the Company : Transo-Pharm, founded in 1987, is a fully licensed global distributor of pharmaceutical components for health and veterinary industries. It supports customers throughout the API li...

Transo-Pharm, founded in 1987, is a fully licensed global distributor of pharmaceutical components for health and veterinary industries. It supports customers throughout the API lifecycle, from development to sales, offering diverse products and qualifying manufacturers for compliance. Acting as a sourcing and regulatory marketing agent, Transo-Pharm has offices in Shanghai, Hong Kong, Singapore, the United States, and an affiliated office in Mumbai. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Transo Pharm Handels GmbH

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

09

HRV Pharma

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...

HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing, manufacturing, and supply services to support partners entering new markets worldwide. HRV Pharma works closely with major pharma and food additive companies and represents over 30 Indian drugmakers, primarily serving Europe, the US, and the Middle East. Headquartered in India, it operates offices in the US, Switzerland, Dubai, Lithuania, and Turkey. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
HRV Global Life Sciences

10

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Isavuconazonium Sulfate

About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...

Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shanghai Minbiotech CB
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Cresemba (Isavuconazonium Sulfate) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of invasive pulmonary aspergillosis.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: $226.0 million Upfront Cash: $3.0 million

Deal Type: Licensing Agreement February 09, 2026

blank

01

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : Cresemba (Isavuconazonium Sulfate) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of invasive pulmonary aspergillosis.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : $3.0 million

February 09, 2026

blank

Details:

Pfizer has Asia Pacific and China rights for Cresemba (isavuconazole), an intravenous and oral azole antifungal.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: $226.0 million Upfront Cash: $3.0 million

Deal Type: Licensing Agreement June 05, 2025

blank

02

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : Pfizer has Asia Pacific and China rights for Cresemba (isavuconazole), an intravenous and oral azole antifungal.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : $3.0 million

June 05, 2025

blank

Details:

Cresemba, with the active ingredient isavuconazonium sulfate, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Asahi Kasei Pharma

Deal Size: $68.6 million Upfront Cash: $7.1 million

Deal Type: Licensing Agreement April 24, 2025

blank

03

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : Cresemba, with the active ingredient isavuconazonium sulfate, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : $7.1 million

April 24, 2025

blank

Details:

Continued strong sales performance of Cresemba® (isavuconazole), an azole antifungal for invasive aspergillosis and mucormycosis, by its license partner Pfizer triggered milestone payment.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: $226.0 million Upfront Cash: $3.0 million

Deal Type: Licensing Agreement March 14, 2025

blank

04

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : Continued strong sales performance of Cresemba® (isavuconazole), an azole antifungal for invasive aspergillosis and mucormycosis, by its license partner Pfizer triggered milestone payment.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : $3.0 million

March 14, 2025

blank

Details:

Under the terms of the license agreement, Asahi Kasei Pharma is granted an exclusive license to develop and commercialize Cresemba (isavuconazole) in Japan.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Asahi Kasei Pharma

Deal Size: $68.0 million Upfront Cash: $7.19 million

Deal Type: Licensing Agreement February 05, 2025

blank

05

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : Under the terms of the license agreement, Asahi Kasei Pharma is granted an exclusive license to develop and commercialize Cresemba (isavuconazole) in Japan.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : $7.19 million

February 05, 2025

blank

Details:

AVIR has license in Canada for Cresemba (isavuconazole sulfate), approved for use in adults and pediatrics from 1 year up to 18 years for invasive aspergillosis and invasive mucormycosis.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Avir Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 28, 2025

blank

06

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : AVIR has license in Canada for Cresemba (isavuconazole sulfate), approved for use in adults and pediatrics from 1 year up to 18 years for invasive aspergillosis and invasive mucormycosis.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : Undisclosed

January 28, 2025

blank

Details:

Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 10, 2024

blank

07

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 10, 2024

blank

Details:

FDA approves expanded use of Cresemba® (isavuconazonium sulfate), an ergosterol inhibitor, in pediatric patients 1 year of age and older with invasive aspergillosis and invasive mucormycosis.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 27, 2024

blank

08

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : FDA approves expanded use of Cresemba® (isavuconazonium sulfate), an ergosterol inhibitor, in pediatric patients 1 year of age and older with invasive aspergillosis and invasive mucormycosis.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 27, 2024

blank

Details:

Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 11, 2024

blank

09

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 11, 2024

blank

Details:

Knight will commercialize Cresemba (isavuconazole sulfate) in Latin America, an azole antifungal for treating adult patients with invasive aspergillosis, licensed for regional distribution.


Lead Product(s): Isavuconazonium Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Knight Therapeutics

Deal Size: Undisclosed Upfront Cash: $11.2 million

Deal Type: Licensing Agreement January 19, 2024

blank

10

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Basilea Pharmaceutica

Switzerland
arrow
Arvo
Not Confirmed

Details : Knight will commercialize Cresemba (isavuconazole sulfate) in Latin America, an azole antifungal for treating adult patients with invasive aspergillosis, licensed for regional distribution.

Product Name : Cresemba

Product Type : Miscellaneous

Upfront Cash : $11.2 million

January 19, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - 186MG

USFDA APPLICATION NUMBER - 207500

read-more

DOSAGE - CAPSULE;ORAL - 74.5MG

USFDA APPLICATION NUMBER - 207500

read-more

DOSAGE - POWDER;INTRAVENOUS - 372MG

USFDA APPLICATION NUMBER - 207501

read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 946075-13-4 / Isavuconazonium Sulfate API manufacturers, exporters & distributors?

Isavuconazonium Sulfate manufacturers, exporters & distributors 1

29

PharmaCompass offers a list of Isavuconazonium Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Isavuconazonium Sulfate manufacturer or Isavuconazonium Sulfate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Isavuconazonium Sulfate manufacturer or Isavuconazonium Sulfate supplier.

API | Excipient name

Isavuconazonium Sulfate

Synonyms

946075-13-4, Cresemba, Isavuconazonium (sulfate), Bal-8557-002, Isavuconazonium sulfate [usan], Chebi:85977

Cas Number

946075-13-4

Unique Ingredient Identifier (UNII)

31Q44514JV

About Isavuconazonium Sulfate

Isavuconazonium Sulfate is the sulfate ester form of isavuconazonium, a prodrug of the triazole antifungal agent isavuconazole, with broad-spectrum antifungal activity. Upon administration, isavuconazonium sulfate is hydrolyzed by plasma esterases to yield the active moiety isavuconazole. Isavuconazole binds to and inhibits the fungal cytochrome P450 family enzyme lanosterol 14-alpha-demethylase (CYP51), which catalyzes the demethylation of lanosterol to yield ergosterol, an important component of the fungal cell membrane. Inhibition of CYP51 leads to a decrease in fungal ergosterol production and disrupts synthesis of the fungal cell membrane, which decreases membrane integrity, increases cell membrane permeability and promotes the loss of essential intracellular elements. This results in fungal cell lysis and death.

Isavuconazole Manufacturers

A Isavuconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Isavuconazole, including repackagers and relabelers. The FDA regulates Isavuconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Isavuconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Isavuconazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Isavuconazole Suppliers

A Isavuconazole supplier is an individual or a company that provides Isavuconazole active pharmaceutical ingredient (API) or Isavuconazole finished formulations upon request. The Isavuconazole suppliers may include Isavuconazole API manufacturers, exporters, distributors and traders.

click here to find a list of Isavuconazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Isavuconazole USDMF

A Isavuconazole DMF (Drug Master File) is a document detailing the whole manufacturing process of Isavuconazole active pharmaceutical ingredient (API) in detail. Different forms of Isavuconazole DMFs exist exist since differing nations have different regulations, such as Isavuconazole USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Isavuconazole DMF submitted to regulatory agencies in the US is known as a USDMF. Isavuconazole USDMF includes data on Isavuconazole's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Isavuconazole USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Isavuconazole suppliers with USDMF on PharmaCompass.

Isavuconazole KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Isavuconazole Drug Master File in Korea (Isavuconazole KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Isavuconazole. The MFDS reviews the Isavuconazole KDMF as part of the drug registration process and uses the information provided in the Isavuconazole KDMF to evaluate the safety and efficacy of the drug.

After submitting a Isavuconazole KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Isavuconazole API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Isavuconazole suppliers with KDMF on PharmaCompass.

Isavuconazole NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Isavuconazole as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Isavuconazole API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Isavuconazole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Isavuconazole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Isavuconazole NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Isavuconazole suppliers with NDC on PharmaCompass.

Isavuconazole GMP

Isavuconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Isavuconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Isavuconazole GMP manufacturer or Isavuconazole GMP API supplier for your needs.

Isavuconazole CoA

A Isavuconazole CoA (Certificate of Analysis) is a formal document that attests to Isavuconazole's compliance with Isavuconazole specifications and serves as a tool for batch-level quality control.

Isavuconazole CoA mostly includes findings from lab analyses of a specific batch. For each Isavuconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Isavuconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Isavuconazole EP), Isavuconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Isavuconazole USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty